Michael Koslowski joined Mission Therapeutics as Chief Medical Officer & EVP Research & Development in 2015.
Michael brings 20 years of experience across academic and biopharmaceutical research and development, specialising in drug target discovery, translational research and clinical validation. Before joining Mission Therapeutics he was VP Clinical Sciences & Early Development at Glenmark Pharmaceuticals responsible for the clinical development of the entire innovative drug portfolio. Prior to this, he established and managed Boehringer Ingelheim’s Global Translational Medicine Experts group. He is a founding member and former Group Head of New Targets & Antibody Development at Ganymed Pharmaceuticals AG, a spin-off from the Universities of Mainz and Zürich that was acquired by Astellas in 2016. Michael held numerous academic positions and was Associate Professor of Molecular Medicine at the University of Mainz.
He holds a Medical Degree from Saarland University and University of Cologne and earned his habilitation in Molecular Medicine from University of Mainz, Germany.
In 2015, Michael was listed in Nature Biotechnology as one of the top 20 translational researchers.